The incidence of colon and rectal cancer in adults younger than 50 years has increased substantially over the latest available 10-year period in several high-income countries, going against a decline or stabilisation trend in the incidence of colorectal cancers within the overall populations of high-income countries.
This is according to an observational study published in The Lancet Gastroenterology & Hepatology journal, which looked at long-term data for colon and rectal cancer incidence in 21 population-based registries across Australia (1983-2012), Canada (1995-2014), Denmark (1978-2012), Ireland (1995-2013), New Zealand (1995-2014), Norway (1953-2014), and the UK (1995-2014).
During the most recent 10-year period up until 2014, the incidence of colon cancer in people aged 0-49 years increased significantly each year in Denmark (by 3.1%), New Zealand (2.9%), Australia (2.9%), and the UK (1.8%). Significant increases in the incidence of rectal cancer each year were also noted in this age group in Canada (by 3.4%), Australia (2.6%), and the UK (1.4%). Increases in the incidence among adults under 50 were most pronounced for rectal cancer, particularly in the 20-29 age group, where rectal cancer incidence increased annually by 18.1% in Denmark and 10.6% in Norway over the past decade.
Across the same time period, significant decreases in incidence of colon cancer per annum were observed in those aged over 50 in Australia (by 1.6%), Canada (1.9%), and New Zealand (3.4%) and of rectal cancer in Australia (2.4%), Canada (1.2%), and the UK (1.2%).
Colorectal cancer is the third most common cancer worldwide, with an estimated 1·8 million new cases diagnosed and 881 000 deaths associated with the disease in 2018.
This study is the first of its kind to comprehensively address and compare age-specific trends in the incidence of colorectal cancer, with its findings identifying divergent trends for different age groups.
"Although the incidence of colorectal cancer in adults younger than 50 years remains much lower compared with that in older age groups, our findings are of concern and highlight the need for action to counteract the rising burden of the disease in younger people. This rise in incidence among younger generations is likely to be driven in part by the changing prevalence of risk factors, such as obesity and poor diet. National programmes to promote healthy diets and physical activity might be the most efficient approach to ensure population-level changes," says the lead author of the study, Dr Marzieh Araghi from International Agency for Research on Cancer, Lyon. 
The authors of the study suggest that the decrease in incidence of colorectal cancer in people over 50 years old in most of the countries studied could be attributed to the introduction of routine screening programmes for premalignant polyps. In Australia, Canada, and the UK, where age-based screening began in 2006, overall decreases in incidence were more pronounced. In those countries where screening programmes began later, such as in Ireland (2012), Denmark (2014), Norway (2012, pilot programme only), and New Zealand (2017), overall rates have remained roughly stable.
Dr Araghi adds, "While population-based screening in people under 50 years old is not considered to be cost-effective due to relatively low incidence numbers, family history could help to identify younger people at high-risk of genetic susceptibility to colorectal cancer, for further assessment. However, future studies are needed to establish the root causes of this rising incidence to enable the development of effective preventive and early-detection strategies."
In terms of limitations, the researchers did not have access to individual-level data on risk factors and screening, so could not examine how changes to these factors interacted with trends in colorectal cancer over time. Furthermore, as noted in the linked commentary, there were only seven high-income countries included in this study; adding data from more countries could strengthen the conclusions on the changing epidemiology of colorectal cancer.
Writing in a linked commentary, Professor Giulia Martina Cavestro from Vita-Salute San Raffaele University, Milan says, "Araghi and colleagues address the debate about lowering the age of screening. In 2018, the American Cancer Society recommended that screening for colorectal cancer should start at age 45 years for all adults. Such an approach is needed, but other initiatives should be endorsed alongside this decision. Furthermore, public awareness campaigns are essential to increase adherence to screening, and more gastroenterology units are likely to be needed. The lower age for screening should not be one-size-fits-all--personal and family history should be taken into account. Among the many risk factors, the importance of taking an accurate family history during a risk assessment cannot be overstated."
NOTES TO EDITORS:
This study was funded by Canadian Partnership Against Cancer, Cancer Council Victoria, Cancer Institute New South Wales, Cancer, Research UK, Danish Cancer Society, National Cancer Registry Ireland, the Cancer Society of New Zealand, NHS England, Norwegian Cancer Society Public Health Agency Northern Ireland, Scottish Government, Wester Australia Department of Health, and Wales Cancer Network.
It was conducted by researchers from International Agency for Research on Cancer, Lyon; National Health Service National Services Scotland, Edinburgh; Cancer Care Ontario, Toronto; Cancer Institute New South Wales, Australia; National Cancer Registry Ireland, Ireland; Cancercare Manitoba, Canada; Danish Cancer Society, Copenhagen; Cancer Society of New Zealand, Wellington; Prince Edward Island Cancer Registry, Charlottetown; BC Cancer, Vancouver; Nova Scotia Health Authority Cancer Care Program, Halifax; Queen's University Belfast, Ireland; Department of Health, Perth; Victorian Cancer Registry, Melbourne; Cancer Registry of Norway, Oslo; NB Cancer Network, Department of Health, Province of New Brunswick; Oslo University Hospital, Oslo.
 Quotes direct from authors and cannot be found in the text of the Article.
The labels have been added to this press release as part of a project run by the Academy of Medical Sciences seeking to improve the communication of evidence. For more information, please see: http://www.sciencemediacentre.org/wp-content/uploads/2018/01/AMS-press-release-labelling-system-GUIDANCE.pdf if you have any questions or feedback, please contact The Lancet press office email@example.com
IF YOU WISH TO PROVIDE A LINK FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: http://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30147-5/fulltext
Peer-reviewed / Observational study / People
The Lancet Gastroenterology & Hepatology